Aravive Management

Management criteria checks 2/4

Aravive's CEO is Gail McIntyre, appointed in Apr 2020, has a tenure of 3.42 years. total yearly compensation is $1.58M, comprised of 32.3% salary and 67.7% bonuses, including company stock and options. directly owns 0.092% of the company’s shares, worth $9.76K. The average tenure of the management team and the board of directors is 3.1 years and 3.2 years respectively.

Key information

Gail McIntyre

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage	32.3%
CEO tenure	3.4yrs
CEO ownership	0.09%
Management average tenure	3.1yrs
Board average tenure	3.2yrs

Recent management updates

Recent updates

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Apr 27

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09

Aravive: Pipeline-In-A-Pill In Oncology

Dec 28

Aravive (ARAV) Investor Presentation - Slideshow

Dec 04

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative

Nov 19

Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China

Nov 10

CEO Compensation Analysis

How has Gail McIntyre's remuneration changed compared to Aravive's earnings?
Date	Total Comp.	Salary	Company Earnings
Jun 30 2023	n/a	n/a	-US$77m
Mar 31 2023	n/a	n/a	-US$113m
Dec 31 2022	US$2m	US$510k	-US$76m
Sep 30 2022	n/a	n/a	-US$60m
Jun 30 2022	n/a	n/a	-US$56m
Mar 31 2022	n/a	n/a	-US$44m
Dec 31 2021	US$2m	US$500k	-US$39m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$30m
Mar 31 2021	n/a	n/a	-US$28m
Dec 31 2020	US$1m	US$404k	-US$31m
Sep 30 2020	n/a	n/a	-US$31m
Jun 30 2020	n/a	n/a	-US$26m
Mar 31 2020	n/a	n/a	-US$24m
Dec 31 2019	US$713k	US$325k	-US$18m
Sep 30 2019	n/a	n/a	-US$65m
Jun 30 2019	n/a	n/a	-US$65m
Mar 31 2019	n/a	n/a	-US$72m
Dec 31 2018	US$101k	US$59k	-US$76m

Compensation vs Market: Gail's total compensation ($USD1.58M) is above average for companies of similar size in the US market ($USD764.66K).

Compensation vs Earnings: Gail's compensation has increased whilst the company is unprofitable.

CEO

Gail McIntyre (60 yo)

3.4yrs

Tenure

US$1,580,639

Compensation

Dr. Gail F. McIntyre, Ph D., CH (ASCP), DABT, serves as President, Chief Executive Officer and Director at Aravive, Inc. since April 08, 2020 and served as its Chief Scientific Officer since February 12, 2...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Fredric Eshelman	Executive Chairman	3.4yrs	US$170.00k	0% $ 0
Gail McIntyre	President	3.4yrs	US$1.58m	0.092% $ 9.8k
Rudy Howard	Chief Financial Officer	1.3yrs	US$798.88k	0.015% $ 1.6k
Jeffrey Cleland	Co-Founder	no data	US$669.98k	no data
Joshua Silverman	Co-Founder	15.7yrs	no data	no data
Marek Ciszewski	Vice President of Investor Relations	no data	no data	no data
Randy Anderson	Senior Vice President of Data Sciences	3.1yrs	no data	no data

3.1yrs

Average Tenure

62.5yo

Average Age

Experienced Management: ARAV's management team is considered experienced (3.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Fredric Eshelman	Executive Chairman	3.4yrs	US$170.00k	0% $ 0
Gail McIntyre	President	3.4yrs	US$1.58m	0.092% $ 9.8k
Michael Rogers	Independent Director	3yrs	US$167.50k	0% $ 0
Sigurd Kirk	Independent Director	2.3yrs	US$147.50k	0% $ 0
Amato Giaccia	Independent Director	4.9yrs	US$162.50k	1.65% $ 174.3k
T. Ho	Independent Director	2.3yrs	US$143.50k	0.075% $ 7.9k
John Hohneker	Independent Director	2.3yrs	US$145.00k	0% $ 0
Eric Zhang	Independent Director	4.9yrs	US$147.50k	1.91% $ 201.5k

3.2yrs

Average Tenure

62yo

Average Age

Experienced Board: ARAV's board of directors are considered experienced (3.2 years average tenure).

Aravive Management

Management criteria checks 2/4

Key information

Recent management updates

Aravive, Inc., Annual General Meeting, Oct 02, 2023

High number of new directors

Aravive, Inc., Annual General Meeting, Sep 22, 2022

Aravive, Inc. Appoints Robert B. Geller as Chief Medical Officer

Aravive, Inc. Appoints Rudy Howard as Chief Financial Officer

High number of new directors

Recent updates

Aravive Receives Letters from Nasdaq Regarding Non-Compliance with Minimum Market Value of its Listed Securities, Minimum Market Value of its Publicly Held Shares, and Minimum Closing Bid Price Requirement

Aravive, Inc., Annual General Meeting, Oct 02, 2023

Consensus revenue estimates decrease by 51%

Aravive, Inc. Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer

Consensus revenue estimates increase by 95%

Aravive, Inc. Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma

Consensus revenue estimates fall by 35%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aravive, Inc. Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian

Aravive Inc. Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 44%

Price target decreased to US$9.80

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aravive, Inc. announced that it has received $41.559988 million in funding from BVF Partners L.P., Eshelman Ventures, LLC, The Invus Group, LLC, and other investors

Consensus forecasts updated

Aravive, Inc. announced that it expects to receive $41.55547 million in funding from BVF Partners L.P., Eshelman Ventures, LLC, The Invus Group, LLC

Consensus forecasts updated

Aravive Receives Third Development Milestone from 3D Medicines

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Consensus revenue estimates increase by 10%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aravive Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Aravive Q2 GAAP EPS misses, revenue beats

Aravive, Inc., Annual General Meeting, Sep 22, 2022

Aravive, Inc. Appoints Robert B. Geller as Chief Medical Officer

Aravive appoints Robert Geller as CMO

Price target decreased to US$18.20

Aravive, Inc. Appoints Rudy Howard as Chief Financial Officer

Aravive, Inc. Presents Updated Clinical Data At Asco Showing Continued Best-In-Class Potential of Batiraxcept in Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Consensus revenue estimates fall by 25%

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

High number of new directors

Consensus forecasts updated

Price target decreased to US$19.75

Aravive, Inc. Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting

Aravive, Inc. Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

High number of new directors

Aravive, Inc. announced that it has received $10.000001 million in funding from Eshelman Ventures, LLC

Aravive, Inc. announced that it expects to receive $10.000001 million in funding from Eshelman Ventures, LLC

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive Inc Announces First Patient Dosed in Phase 1B/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma

Consensus revenue estimates increase to US$7.34m

Aravive, Inc.(NasdaqGS:ARAV) dropped from Russell Microcap Growth Index

Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Consensus revenue estimates increase to US$4.10m

Aravive, Inc. Plans to Investigate AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer

Aravive EPS beats by $0.01, misses on revenue

Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Insider exercised options to buy US$318k worth of stock.

Consensus revenue estimates increase to US$3.11m

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Full year 2020 earnings released: US$1.93 loss per share (vs US$1.57 loss in FY 2019)

Aravive, Inc. Announces Updated Data from Its Phase 1B Trial Evaluating Avb-500 in Platinum Resistant Ovarian Cancer

Aravive, Inc. Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma

New 90-day high: US$6.85

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Dr. Ray Tabibiazar Announces to Step Down from the Aravive Board of Directors

Aravive: Pipeline-In-A-Pill In Oncology

New 90-day high: US$6.51

Aravive (ARAV) Investor Presentation - Slideshow

Aravive, Inc. Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative